Coronary calcification: Achilles’ heel in the assessment for coronary artery disease in patients with symptomatic angina?
- First Online:
- Cite this article as:
- Makaryus, J.N. & Makaryus, A.N. Int J Cardiovasc Imaging (2009) 25: 855. doi:10.1007/s10554-009-9535-1
- 179 Views
Coronary calcium quantification has emerged as a reliable and independent predictor of adverse cardiovascular events. Advances in multidetector scanning and imaging protocols have resulted in decreased contrast volumes, shorter scan times, and decreased radiation exposure, as well as improved spatial resolution and enhanced image quality. In subsets of patients with high calcium scores (particularly ≥400), however, the artifactual effects and scatter associated with radiodense calcium deposits have limited the specificity of CT coronary angiography (CTCA) in delineating the extent of clinically significant coronary artery disease (CAD). In the present study in the International Journal of Cardiovascular Imaging, Meijs et al.  conduct a multicenter prospective analysis of the diagnostic performance of 64-CTCA to predict the incidence of CAD in 360 patients who had been referred for conventional invasive coronary angiography (ICA) on the basis of symptomatic angina (stable and unstable) regardless of coronary calcium score (CS) over a 2-year time interval. As expected, the incidence of significant CAD correlated with increased CS. In patients with a CS ≥ 400, the prevalence of significant CAD was 87% as compared to 24% in those with a CS < 10. The specificity of CTCA as well as the positive likelihood ratio for significant CAD decreased significantly, however, as the CS increased. In patients with a CS < 10, the specificity was 89% (95%CI 76–96%) while in patients with CS > 400, the specificity was only 20% (95%CI 5–49%) .
The findings of this study are not inconsistent with the current literature, though the dramatic decline in specificity with increasing CS demonstrates a significant degree of inter-study variability. Early studies comparing the diagnostic capabilities of CTCA with ICA often excluded patients with elevated baseline CS as a result of the negative impact of high CS on CTCA accuracy or the inability to assess the presence or absence of stenosis with increased calcification [2–4]. Studies which did include arterial segments with high levels of calcification usually denoted a significant decline in the diagnostic capability of the test. For example, the multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial which enrolled 230 patients regardless of CS, demonstrated a decline of specificity of CTCA for the 50% threshold CAD level from 86.3% in patients with CS ≤ 400 to 52.6% in patients with CS > 400 (P < 0.0003) .
Studies of the implications of reduced specificity of CTCA have suggested that patients with very high calcium scores should forego multidetector coronary CT angiography in favor of ICA given the decreased accuracy of the test with increased CS and the likelihood that individuals with very high CS have obstructive disease and will require invasive angiography anyway . Severe coronary calcification impedes the ability to adequately assess the degree of lumen compromise and has repeatedly been shown to limit the test’s diagnostic capability [7–9]. Given the lack of additional information likely to be gleaned from CTCA in both patients with a high pretest probability as well as those with a very low pretest probability of coronary artery disease, the test remains most useful primarily in patients with an intermediate likelihood of cardiovascular disease and symptoms potentially attributable to CAD . Hence, the necessity of the test in high-risk individuals with symptomatic angina (and thus high pretest probability of coronary disease) is difficult to justify on the basis of current data, notwithstanding occasional data which may indicate minimal or no effect of CS on the specificity of the test . This acknowledgement is particularly relevant given the low probability that CTCA will preclude invasive angiography in these patients. This philosophy is reflected in the joint appropriateness criteria for cardiac CT published in 2006 .
The limited specificity of CTCA in detecting clinically relevant coronary artery stenoses in patients with high CS correlates with the recent trend to focus upon improving visualization of noncalcified, lipid-laden/mixed lesions rather than relying solely upon calcium scoring to estimate the risk of adverse cardiovascular disease events. The recently published Multi-Ethnic Study of Atherosclerosis (MESA) trial emphasized that even asymptomatic individuals with very low CS (1–10) may be at risk of significant cardiovascular disease events compared to individuals with a CS of 0 . In addition, 13–18% of coronary arteries with ≥75% stenosis had a CS of 0, raising further concerns about relying too heavily upon calcium scoring .
At our institution, we retrospectively determined that despite a relatively equivalent likelihood of cardiovascular disease events between males and postmenopausal females in an age and risk-factor matched cohort, females had significantly lower calcium scores in each of the four major coronary vessels reflecting the importance of lipid-laden and mixed plaques in leading to CAD events .
The study by Meijs et al.  solidifies an accepted concept in the field of cardiac computed tomography; namely, that the test is extremely useful when used under the appropriate clinical circumstances. While constantly improving technology with enhanced temporal and spatial resolution as well as newer study protocols have successfully minimized the reduction of diagnostic performance attributable to motion artifacts, increasing degrees of coronary calcification may still limit the specificity of the test in high-risk individuals. Thus, while the future is promising and the number of appropriate indications for CTCA is likely to increase, current technology still dictates that the test should primarily be reserved for intermediate-risk individuals in whom a positive or negative scan may alter clinical pathways and CTCA may serve as a true “gateway” for invasive angiography.